Breaking News Instant updates and real-time market news.

SHPG

Shire

$174.37

1.15 (0.66%)

, RHHBY

Roche

$0.00

(0.00%)

14:31
08/07/18
08/07
14:31
08/07/18
14:31

Shire denied bid to have Roche's Hemlibra pulled from market, Bloomberg says

Roche (RHHBY) can continue selling the hemophilia drug as a judge denied Shire's (SHPG) request for an injunction, according to Bloomberg.

SHPG

Shire

$174.37

1.15 (0.66%)

RHHBY

Roche

$0.00

(0.00%)

  • 08

    Aug

  • 21

    Dec

SHPG Shire
$174.37

1.15 (0.66%)

04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
RHHBY Roche
$0.00

(0.00%)

06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.80

-3 (-1.06%)

10:33
08/15/18
08/15
10:33
08/15/18
10:33
Technical Analysis
Technical Take: SPDR S&P 500 ETF breaks additional support »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.80

-3 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$113.29

0.19 (0.17%)

, MAR

Marriott

$119.80

-1.78 (-1.46%)

10:32
08/15/18
08/15
10:32
08/15/18
10:32
Hot Stocks
Marriott expands PepsiCo relationship with new multiyear deal »

PepsiCo (PEP) and…

PEP

PepsiCo

$113.29

0.19 (0.17%)

MAR

Marriott

$119.80

-1.78 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HMNY

Helios and Matheson

$0.04

-0.0135 (-27.00%)

10:32
08/15/18
08/15
10:32
08/15/18
10:32
Hot Stocks
Helios and Matheson: Creating a 'more sustainable path' for MoviePass »

"We far exceeded our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.04

-0.0141 (-28.20%)

10:31
08/15/18
08/15
10:31
08/15/18
10:31
Hot Stocks
Helios and Matheson issues progress report on MoviePass »

Helios and Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:31
08/15/18
08/15
10:31
08/15/18
10:31
General news
Crude inventories for week of August 10 »

Crude oil inventories…

BSX

Boston Scientific

$34.05

0.36 (1.07%)

10:30
08/15/18
08/15
10:30
08/15/18
10:30
Options
Bullish option play in Boston Scientific as shares see relative strength »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 23

    Aug

10:30
08/15/18
08/15
10:30
08/15/18
10:30
General news
The 0.1% U.S. June business inventory rise »

The 0.1% U.S. June…

10:30
08/15/18
08/15
10:30
08/15/18
10:30
General news
U.S. VIX not dead yet, surging 20% »

U.S. VIX not dead yet,…

WEN

Wendy's

$17.71

-0.13 (-0.73%)

10:28
08/15/18
08/15
10:28
08/15/18
10:28
Conference/Events
Wendy's participates in a conference call with Stephens »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

CUR

Neuralstem

$1.19

(0.00%)

10:27
08/15/18
08/15
10:27
08/15/18
10:27
Earnings
Neuralstem reports Q2 EPS (4c) vs. (39c) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
08/15/18
08/15
10:25
08/15/18
10:25
Conference/Events
Vertical Group analyst to hold an analyst/industry conference call »

Metals/Mining &…

WMT

Walmart

$89.74

-1.065 (-1.17%)

, AMZN

Amazon.com

$1,892.64

-27.08 (-1.41%)

10:24
08/15/18
08/15
10:24
08/15/18
10:24
Earnings
On The Fly: What to watch in Wal-Mart earnings report »

WalMart (WMT) is…

WMT

Walmart

$89.74

-1.065 (-1.17%)

AMZN

Amazon.com

$1,892.64

-27.08 (-1.41%)

NFLX

Netflix

$328.11

-9.38 (-2.78%)

MSFT

Microsoft

$107.48

-1.67 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

EVBG

Everbridge

$54.40

-0.04 (-0.07%)

10:23
08/15/18
08/15
10:23
08/15/18
10:23
Conference/Events
Everbridge management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

NVDA

Nvidia

$258.69

-2.78 (-1.06%)

, WDC

Western Digital

$61.75

-3.23 (-4.97%)

10:22
08/15/18
08/15
10:22
08/15/18
10:22
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

NVDA

Nvidia

$258.69

-2.78 (-1.06%)

WDC

Western Digital

$61.75

-3.23 (-4.97%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GWPH

GW Pharmaceuticals

$132.44

-1.04 (-0.78%)

HAS

Hasbro

$97.55

-0.59 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WU

Western Union

$18.74

-0.075 (-0.40%)

10:20
08/15/18
08/15
10:20
08/15/18
10:20
Options
Put buyers in Western Union »

Put buyers in Western…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

M

Macy's

$37.10

-4.77 (-11.39%)

10:17
08/15/18
08/15
10:17
08/15/18
10:17
Hot Stocks
Macy's says SG&A dollars for the year expected to be higher than last year »

CFO Paula Price says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 17

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/15/18
08/15
10:17
08/15/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CISN

Cision

$16.33

0.07 (0.43%)

, OBSV

ObsEva

$13.25

0.27 (2.08%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CISN

Cision

$16.33

0.07 (0.43%)

OBSV

ObsEva

$13.25

0.27 (2.08%)

IDRA

Idera Pharmaceuticals

$9.06

0.545 (6.40%)

DTE

DTE Energy

$112.00

0.97 (0.87%)

TELL

Tellurian

$7.10

-0.01 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

NLSN

Nielsen

$25.50

-0.57 (-2.19%)

, UNP

Union Pacific

$148.61

-1.56 (-1.04%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NLSN

Nielsen

$25.50

-0.57 (-2.19%)

UNP

Union Pacific

$148.61

-1.56 (-1.04%)

KMB

Kimberly-Clark

$113.90

2.8 (2.52%)

WDC

Western Digital

$61.77

-3.21 (-4.94%)

TSRO

Tesaro

$27.70

-0.37 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 26

    Aug

  • 06

    Nov

NVDA

Nvidia

$259.49

-1.98 (-0.76%)

, HAS

Hasbro

$97.66

-0.48 (-0.49%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NVDA

Nvidia

$259.49

-1.98 (-0.76%)

HAS

Hasbro

$97.66

-0.48 (-0.49%)

INCY

Incyte

$67.21

0.76 (1.14%)

NSC

Norfolk Southern

$171.79

-0.39 (-0.23%)

PZZA

Papa John's

$42.50

-0.5 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 26

    Aug

  • 06

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
U.S. NAHB housing market index fell 1 tick to 67 in August »

U.S. NAHB housing market…

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
Treasury Action: yields slumped back to lows »

Treasury Action: yields…

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
Breaking General news story  »

Week of 8/10 EIA…

LEG

Leggett & Platt

$43.14

-0.57 (-1.30%)

10:13
08/15/18
08/15
10:13
08/15/18
10:13
Conference/Events
Leggett & Platt management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.